Literature DB >> 11994112

Voice gains following thyroplasty may improve over time.

C R Billante1, J Clary, P Childs, J L Netterville.   

Abstract

Type I thyroplasty for unilateral vocal fold paralysis restores voice. The purpose of this study was to evaluate measures of voice before thyroplasty, and at 3 months and 1 year after surgery. Of interest was whether vocal improvement in the first weeks after surgery was maintained or even enhanced over time. A total of 40 patients with unilateral paralysis underwent type I thyroplasty with or without arytenoid adduction. Perceptual, acoustic and aerodynamic measures of voice were studied. Perceptual analysis determined that optimal postoperative voice quality evolved over the first year. Acoustic indices of perturbation demonstrated progressive improvement over 12 months, whereas pitch and intensity ranges were increasingly extended. Postoperative glottal flow rates were normalized and phonation times were significantly longer, with benefits maintained over time. All perceptual, aerodynamic and acoustic measures of voice were improved 3 months after thyroplasty, with many measures further improved at 1 year. Such findings provide evidence that voice outcome progressively evolves over the first 12 months after surgery.

Entities:  

Mesh:

Year:  2002        PMID: 11994112     DOI: 10.1046/j.1365-2273.2002.00536.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  3 in total

Review 1.  [Therapy for unilateral vocal fold palsy].

Authors:  M Schuster; U Eysholdt
Journal:  HNO       Date:  2005-09       Impact factor: 1.284

Review 2.  Voice outcome indicators for unilateral vocal fold paralysis surgery: a review of the literature.

Authors:  G Desuter; M Dedry; B Schaar; J van Lith-Bijl; P P van Benthem; E V Sjögren
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-20       Impact factor: 2.503

3.  Multidimensional assessment of functional outcomes of medialization thyroplasty.

Authors:  Virgilijus Uloza; Ruta Pribuisiene; Viktoras Saferis
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-12-10       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.